PERK antibody (AA 530-850)

Catalog No. ABIN6243642

The Mouse Monoclonal anti-PERK antibody has been validated for WB. It is suitable to detect PERK in samples from Human, Mouse and Rat.

Quick Overview for PERK antibody (AA 530-850) (ABIN6243642)

Target: PERK (EIF2AK3) (Eukaryotic Translation Initiation Factor 2-alpha Kinase 3 (EIF2AK3))

Reactivity: Human, Mouse, Rat

Host: Mouse

Clonality: Monoclonal

Conjugate: This PERK antibody is un-conjugated

Application: Western Blotting (WB)

Clone: 1385CT582-4-39

Product Details anti-PERK Antibody

Binding Specificity: AA 530-850

Purification: This antibody is purified through a protein G column, followed by dialysis against PBS.

Immunogen: This EIF2AK3 antibody is generated from a mouse immunized with a recombinant protein conjugated synthetic peptide between 530-850 amino acids from human EIF2AK3.

Isotype: IgG1

Application Details

Application Notes: WB: 1:250-1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified monoclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

Target Details for PERK

Target: PERK (EIF2AK3) (Eukaryotic Translation Initiation Factor 2-alpha Kinase 3 (EIF2AK3))

Alternative Name: EIF2AK3

Background: Phosphorylates the alpha subunit of eukaryotic translation-initiation factor 2 (EIF2), leading to its inactivation and thus to a rapid reduction of translational initiation and repression of global protein synthesis. Serves as a critical effector of unfolded protein response (UPR)-induced G1 growth arrest due to the loss of cyclin-D1 (CCND1). Involved in control of mitochondrial morphology and function (By similarity).

Molecular Weight: 125216

UniProt: Q9NZJ5

Pathways: Hormone Transport, ER-Nucleus Signaling, Positive Regulation of Endopeptidase Activity, Hepatitis C, Unfolded Protein Response